Sharemaestro company-news research for Pfizer Inc. (PFE), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
BUE
Argentina
Measured evidence
Company news sentiment
PFE news sentiment
Pfizer Inc.
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone56Neutral is 50
Balanced news tone
85/100 evidence confidence
100% direct company focus
29 current stories across 4 publishers
Checking for newer PFE headlines
An earlier measured reading is retained below: 46/100 from 23 articles on 12 Aug 04:59. Current source headlines are being refreshed without delaying this page.
Current company news
Price moving ahead of tone
Balanced news tone is drawn from 29 fresh independent stories, including 29 company-specific items across 4 publishers.
Latest source headline Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ... finance.yahoo.com · 13 Aug 2026 05:01What supports the read
29 current stories are mapped specifically to PFE.
The read spans 4 publishers rather than depending on one outlet.
Cross-story agreement is 79/100, indicating a comparatively coherent tape.
What tempers the read
Price is moving more forcefully than the current news tone suggests.
56/100
Weighted toneBalanced news tone
85/100
Evidence confidencehigh confidence
100%/100
Company focus29 direct stories
79/100
Evidence agreement21/100 dispersion
News history
Tone and story flow over 21 days
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth100
25.81 effective storiesSource breadth80
4 independent publishersDirect relevance100
company-specific evidence shareFreshness75
recency-weighted evidenceAgreement79
cross-story consistencySource independence37
lower publisher concentrationPrice context
Sentiment against the 26-week price path
Price is moving more forcefully than the current news tone suggests.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
News subjects
What is shaping the score
Earnings5620 stories · 69%
Market update464 stories · 14%
Regulatory and legal712 stories · 7%
Deals and strategy432 stories · 7%
Analyst action751 stories · 3%
Source mix
Where the evidence comes from
finance.yahoo.com5920 stories · 69%
seekingalpha.com507 stories · 24%
nasdaq.com281 stories · 3%
MarketWatch461 stories · 3%
Recurring subjects
Subjects appearing most often
Earnings16Guidance8Clinical Trials8Biotech8Pharma7Oncology6Fda Approval6Financial Results5Earnings Per Share5Dividends5
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#127Tone
finance.yahoo.comDirect company coverage
Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ...
This article first appeared on GuruFocus. Cash and Cash Equivalents: $50.8 million as of June 30, 2026, excluding net proceeds from the July 2026 royalty financing. Revenue: No revenue for Q2 2026, compared to $14.2 million in Q2 2025, primarily due to prior collaboration revenue from Pfizer and GSK being fully realized. R&D Expenses: $3.4 million in Q2 2026, down from $10.7 million in Q2 2025, due to reduced clinical activity following the early completion of the Utebzi Phase 3 trial. G&A Expenses: $6.5 million in Q2 2026, up from $5.9 million in Q2 2025, driven by higher business development
Balance SheetClinical TrialsEarningsFda ApprovalFinancial ResultsImmunology
- Published
- 13 Aug 2026 05:01
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#238Tone
finance.yahoo.comDirect company coverage
Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
VALNEVA SE Total product sales of €64.0 million In-line with expectations; full-year guidance of €135 -150 million reaffirmed Solid cash position of €121.5 million as of end June 2026 Reflects disciplined cash management and proceeds from the recent reserved offering1 Restructuring program implemented with positive P&L and cash flow impacts expected in the second half of the year and beyond Regulatory decisions for Lyme disease vaccine candidate expected in the next twelve months2 Pfizer remains optimistic about obtaining registration for the vaccine candidate3 Lyon (France), August 13, 2026 –
Clinical TrialsEarningsFinancial ResultsGuidanceRestructuringTotal Revenue
- Published
- 13 Aug 2026 05:00
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#387Tone
finance.yahoo.comDirect company coverage
5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call
5 Insightful Analyst Questions From Pfizer's Q2 Earnings Call Pfizer's second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company's performance was shaped by strong execution in its non-COVID portfolio, with management highlighting robust revenue contributions from acquired brands and recent launches. CEO Albert Bourla attributed operational progress to "continued strategic progress" and emphasized the value generated by recent acquisitions such as Seagen and Biohaven. Management also pointed to the success of brands
Clinical TrialsDividendsEarningsPharmaRevenue Guidance
- Published
- 13 Aug 2026 02:29
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#486Tone
finance.yahoo.comDirect company coverage
Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?
Bristol Myers Squibb BMY is navigating a revenue mix shift as growth products portfolio now assumes a larger role in the business, helping mitigate the impact of declining sales from mature products facing generics. The growth portfolio — including Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyku, Krazati and Cobenfy — is becoming central to top-line resilience. Sales from this segment rose 13% in the first half of 2026, lifting its contribution to 56% of total revenues from 51.8% in the first half of 2025. The stronger mix underscores improving r
Immuno OncologyOncologyPharmaRevenue Growth
- Published
- 12 Aug 2026 18:36
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#538Tone
seekingalpha.comDirect company coverage
Tigo Energy downgraded at Roth after weak revenue guidance
[Aerial view of large electrical power plant with many rows of solar photovoltaic panels for producing clean ecological electric energy in morning. Renewable electricity with zero emission concept.] Bilanol/iStock via Getty Images Tigo Energy (TYGO [https://seekingalpha.com/symbol/TYGO]) down 5.2% in Wednesday's trading as Roth Capital downgraded shares of the solar and energy storage firm to Neutral from Buy with a $1.30 price target, slashed from $7 previously, reflecting "materially weaker growth visibility" following its Q2 results. Tigo Energy (TYGO [https://seekingalpha.com/symbol/TYGO])
DowngradeEarningsGuidancePrice TargetPrice TargetSolar
- Published
- 12 Aug 2026 18:21
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#650Tone
finance.yahoo.comDirect company coverage
Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?
Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product launches, strategic acquisitions and the continued growth of several established brands. Pfizer's non-COVID portfolio is increasingly becoming the company's primary engine of growth, helping offset the sharp decline in Comirnaty and Paxlovid revenues. The latest second-quarter 20
EarningsGuidanceObesityOncologyPharmaRevenue Growth
- Published
- 12 Aug 2026 15:03
- Catalyst
- Deals and strategy
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#754Tone
seekingalpha.comDirect company coverage
U.K. regulator reaffirms safety of childhood vaccination
[Syringe drawing liquid medication from medical vial] zhikun sun/iStock via Getty Images Days after President Donald Trump ordered major changes to the U.S. childhood immunization schedule, the U.K. drug regulator on Wednesday reaffirmed the safety of pediatric vaccination, noting it remains one of the safest and most effective ways to fight many severe infectious diseases. Issuing an executive order to reduce the number of childhood vaccines administered in the U.S. and split the measles, mumps, and rubella vaccination into three separate shots on Monday, Trump suggested a link between vaccin
HealthcareRegulationSplitVaccines
- Published
- 12 Aug 2026 13:13
- Catalyst
- Market update
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#875Tone
finance.yahoo.comDirect company coverage
Why Revolution Medicines May Be Big Pharma’s Next Takeover Target
Quick Read RVMD has surged 492% over one year on daraxonrasib's landmark pancreatic cancer data showing 13.2 versus 6.7 months median overall survival. MRK ranks as the most likely acquirer, with Keytruda's patent cliff mounting pressure and CEO Robert Davis pledging to diversify its growth portfolio. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor) Revolution Medicines (NASDAQ:RVMD) closed at $205.55 on August 11, 2026, giving the pre-commercial oncology platform
Balance SheetBiotechFda ApprovalM AOncologyPrice Target
- Published
- 12 Aug 2026 12:50
- Catalyst
- Analyst action
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#961Tone
finance.yahoo.comDirect company coverage
The S&P 500 Yield Is the Lowest in History: 5 Members of the Legacy Index Yield 6% or More
Quick Read The S&P 500's combined dividend yield hit a record-low 1.04%, but five index members still deliver dividends of 6% or more, all rated Buy. General Mills (GIS) yields 6.9% at just 10x 2026 earnings, while Verizon (VZ) has raised its dividend for 20 consecutive years. Since 1926, dividends have contributed 32% of the S&P 500's total return, and payers have delivered more than double the returns of non-payers. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor
Consumer StaplesDividend PaymentsDividendsFree Cash FlowPharmaPrice Target
- Published
- 12 Aug 2026 12:15
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1062Tone
finance.yahoo.comDirect company coverage
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna settlement in July and expects to return up to approximately $230M in capital to Arbutus shareholders Filed three international patent enforcement lawsuits against Pfizer and BioNTech related to lipid nanoparticle (LNP) technology Achieved alignment with the U.S. Food and Drug Administration (FDA) on a proposed imdusiran Phase 2b clinical trial design WARMINSTER, Pa., Aug. 12, 2026 (GLOB
BiotechClinical TrialsEarningsFinancial ResultsNet IncomePatent Litigation
- Published
- 12 Aug 2026 11:30
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1165Tone
finance.yahoo.comDirect company coverage
Pfizer (PFE) Agreed To A $44 Million Chantix Settlement
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Pfizer (NYSE:PFE) agreed to a US$44 million class action settlement related to its smoking cessation drug Chantix, addressing claims tied to product safety disclosures. The company reported positive topline Phase 3 results for LITFULO in adults and adolescents with nonsegmental vitiligo, highlighting progress in its immunology pipeline. Both developments arrive as investors track Pfizer's legal exposures alongside late stage trial data that could inform future portfolio and r
Balance SheetBiopharmaceuticalsClass ActionClass Action SettlementClinical TrialsImmunology
- Published
- 12 Aug 2026 05:39
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1246Tone
MarketWatchDirect company coverage
Pfizer Inc. stock underperforms Tuesday when compared to competitors
- Published
- 11 Aug 2026 20:37
- Catalyst
- Market update
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1359Tone
finance.yahoo.comDirect company coverage
BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge
BridgeBio Pharma BBIO reported a second-quarter 2026 loss of 78 cents per share, wider than the Zacks Consensus Estimate of a loss of 64 cents. Despite the miss, the figure improved compared to the year-ago loss of 95 cents. Revenues surged 120% year over year to $243.7 million, beating the Zacks Consensus Estimate of $222.6 million. This growth was primarily driven by its sole marketed drug, Attruby. Year to date, BridgeBio's shares have gained 11% compared with the industry's 7% growth.Zacks Investment Research Image Source: Zacks Investment Research BBIO's Attruby Sales Drive the Top Line A
BiotechClinical TrialsEarningsEarnings Per ShareEarnings ResultsFda Approval
- Published
- 11 Aug 2026 16:45
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1482Tone
finance.yahoo.comDirect company coverage
Pfizer (PFE) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 11:00 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer - Albert Bourla Chief Financial Officer - David Denton Incoming Interim Chief Financial Officer and Executive Vice President - Cecile Guegan Chief Scientific Officer - Chris Boshoff Chief Investor Relations Officer and Senior Vice President - Francesca DeMartino Full Conference Call Transcript Operator: Good day, everyone, and welcome to Pfizer's Second Quarter 2026 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call
Balance SheetDividendsEarningsEarnings Per ShareFourth QuarterGrowth Rate
- Published
- 11 Aug 2026 16:00
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1569Tone
finance.yahoo.comDirect company coverage
The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases"
A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the nominees for the 2026 Prix Galien USA Awards in the "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases" categories. Winners will be honored at the Prix Galien USA Awards Ceremony on October 29, 2026, at the American Museum of Natural History in New York City.logo "We are proud to recog
BiotechFda ApprovalPharmaceuticalsRare Diseases
- Published
- 11 Aug 2026 13:00
- Catalyst
- Regulatory and legal
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1629Tone
finance.yahoo.comDirect company coverage
Pfizer Inc. (PFE) vs. BioNTech SE (BNTX): Which Pharma Giant Is Better Positioned for the Post-COVID Era?
Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), two companies forever linked by their historic COVID-19 vaccine partnership, reported Q2 2026 earnings alongside major strategic announcements. While the European Commission authorized their updated XFG-adapted COVID-19 vaccine on July 29, the two partners are traveling down very different paths. One is leveraging massive scale and aggressive cost-cutting to protect profits, while the other is absorbing heavy losses to fund a corporate transition into oncology under new leadership.Pfizer vs. BioNTech: Which Pharma Giant Is Better Positioned
Balance SheetCovid 19DividendsEarningsInstitutional InvestorsOncology
- Published
- 11 Aug 2026 12:31
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1770Tone
finance.yahoo.comDirect company coverage
S&P 500 Companies' Quarterly Earnings Growth Eases Amid Healthcare Drop, Oppenheimer Says
S&P 500 companies' quarterly earnings growth rate eased from a week ago amid a drop in the healthcar PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in
Growth RateQuarterly Earnings
- Published
- 10 Aug 2026 18:02
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1874Tone
finance.yahoo.comDirect company coverage
Glioma Market is Set for Tremendous Growth at a CAGR of 15% During the Study Period (2022–2036), as Novel Targeted Therapies and Immunotherapies are Gaining Momentum | DelveInsight
DelveInsight Business Research LLP The glioma market is expected to witness steady growth over the coming years, driven by the rising incidence of primary brain tumors, increasing awareness, and advances in diagnostic technologies. The market is also benefiting from a robust pipeline of therapies, including Regorafenib (Bayer), AV-GBM-1 (Aivita Biomedical), Enzastaurin (DB-102) (Denovo Biopharma), Paxalisib (GDC-0084) (Kazia Therapeutics), and others, aimed at improving patient outcomes. New York, USA, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Glioma Market is Set for Tremendous Growth at a CAGR of 15
BiotechClinical TrialsFda ApprovalGliomaMarket Research ReportsPharma
- Published
- 10 Aug 2026 17:00
- Catalyst
- Regulatory and legal
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1929Tone
finance.yahoo.comDirect company coverage
How smart investors use ETFs to legally bypass IRS wash sale rules
Tax loss harvesting is a very effective strategy for investors to trim their tax bill each year. Selling underperforming holdings in a taxable account for a loss can help offset gains realized elsewhere. You can use losses to offset realized capital gains and can use up to $3,000 of capital losses to offset other income each year. One potential roadblock, though, is the IRS wash sale rule (IRS section 1091). What is the wash sale rule? The wash sale rule disallows the loss if you purchase the same or a "substantially identical" security within a 61-day window (30 days before the sale, the day
EtfsHealthcareIndex FundsInvesting StrategiesTax Loss Harvesting
- Published
- 10 Aug 2026 15:17
- Catalyst
- Market update
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#2086Tone
finance.yahoo.comDirect company coverage
BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?
Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 16.2% over the past three months compared with the industry's growth of 6.8%. The stock has also outperformed both the sector and the S&P 500. BMY Outperforms Industry, Sector & S&P 500 IndexZacks Investment Research Image Source: Zacks Investment Research The company reported better-than-expected second-quarter results on July 30, supported by robust demand for Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag. Results were also boosted by strong Eliquis performan
BiotechEarningsGeneric CompetitionGuidanceImmuno Oncology
- Published
- 10 Aug 2026 15:15
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#2126Tone
finance.yahoo.comDirect company coverage
Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock
Pfizer PFE stock has risen 6.9% since it announced second-quarter 2026 results on Aug. 4. Pfizer delivered a solid second quarter, beating estimates for both earnings and revenues. While earnings growth was flat year over year, revenues rose 1% on an operational basis. Strength in non-COVID products continued to offset declining sales of its COVID products, Comirnaty (COVID-19 vaccine - in partnership with BioNTech [BNTX]) and Paxlovid (oral antiviral). Excluding sales from BioNTech-partnered Comirnaty and Paxlovid, revenues increased 5% operationally. Pfizer also raised the lower end of its 2
EarningsEarnings GrowthEarnings Per ShareObesityOncologyPatent Cliff
- Published
- 10 Aug 2026 13:17
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#2243Tone
seekingalpha.comDirect company coverage
Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus
Wall Street’s major market averages ended higher on Friday after July's nonfarm payrolls surprised to the downside, showing an unexpected contraction in employment. The blue-chip Dow edged up 0.3%, the benchmark S&P 500 gained 0.62%, and the tech-focused Nasdaq Composite jumped 1.3%. The S&P 500 Health Care Index Sector (XLV [https://seekingalpha.com/symbol/XLV]) gained 1.92% during the week. The top S&P 500 healthcare gainers and losers for the last week are as follows: TOP GAINERS: Charles River Laboratories International (CRL [https://seekingalpha.com/symbol/CRL]) +15.04% Veeva Systems (VEE
Consensus EstimateEarningsEarnings Per ShareGuidanceHealthcareM A
- Published
- 09 Aug 2026 13:05
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#2334Tone
seekingalpha.comDirect company coverage
SA Asks: What's the outlook for Big Pharma M&A?
[Medical research with pipette and test tube, DNA analysis, biotechnology, genetic science and healthcare] jittawit.21 Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) was in merger talks with AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), a development that was later denied by unnamed sources to Reuters. We asked Seeking Alpha analysts Stephen Ayers [https://seekingalpha.com/author/stephen-ayers], ALLKA Research [https://seekingalpha.com/author/allka-research], and Chris DeMuth
BiotechFda ApprovalM&aM AOncologyPharma
- Published
- 08 Aug 2026 19:28
- Catalyst
- Deals and strategy
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#2457Tone
seekingalpha.comDirect company coverage
Earnings Scorecard: 95% of healthcare firms deliver EPS wins this week
Major healthcare heavyweights, including Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), Merck (MRK [https://seekingalpha.com/symbol/MRK]), and Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]), reported their quarterly earnings this week, pushing the healthcare sector into positive territory after five consecutive sessions of losses. The State Street Health Care Select Sector SPDR ETF [https://seekingalpha.com/symbol/XLV] (XLV [https://seekingalpha.com/symbol/XLV]) rose 1.36% in the week so far. On a YTD basis, XLV has added more than 5%; however, it is lagging behind the broader S&P
BiotechEarningsEarnings NewsGuidanceHealthcarePharma
- Published
- 08 Aug 2026 15:15
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#2559Tone
seekingalpha.comDirect company coverage
Insider trades: Microsoft, Meta, Pfizer among notable names
[Meta European head office] Derick Hudson Insider transactions were seen across major firms this week, including Microsoft (MSFT [https://seekingalpha.com/symbol/MSFT]) and Meta (META [https://seekingalpha.com/symbol/META]). The following trades took place between August 3 and August 7. * Microsoft (MSFT [https://seekingalpha.com/symbol/MSFT]) saw two executives divest a small part of their positions in the company this week. EVP and Chief Marketing Officer Takeshi Numoto sold 4,810 shares at $496.48 each for ~$2.39M. The transaction represented about 10.13% of his direct holdings, leaving him
EquitiesInsider Transactions
- Published
- 08 Aug 2026 15:03
- Catalyst
- Market update
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#2685Tone
seekingalpha.comDirect company coverage
Earnings Scoreboard: 86% of S&P 500 reporting firms top EPS estimates as 79% post Y/Y profit growth
[Rolled newspaper with the headline Quarterly Results] Zerbor S&P 500 earnings activity accelerated this week, with more than 130 index members reporting quarterly results that provided key insights into corporate margin health, spending trends, and overall macroeconomic strength. EARNINGS ROUNDUP: * BOTTOM LINE (EPS): Out of 133 reporting companies, 114 topped consensus estimates, 15 fell short, and 4 met expectations, with 105 firms posting year-over-year earnings growth. * TOP LINE (REVENUE): Sales performance remained robust, with 97 companies beating revenue projections and 36 missing, wh
EarningsEarnings GrowthEarnings NewsFinancial ResultsFree Cash FlowGuidance
- Published
- 08 Aug 2026 13:30
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#2724Tone
finance.yahoo.comDirect company coverage
Novavax (NVAX) Is Up 8.6% After Beating Q2 Estimates And Expanding Big-Pharma Partnerships - What's Changed
In early August 2026, Novavax reported Q2 2026 revenue of US$56.7 million, sharply lower than the prior year, and moved from net income to a net loss of US$53.39 million, translating into basic and diluted losses of US$0.32 per share from continuing operations. Alongside the weak year-on-year comparisons, Novavax beat analyst expectations for both revenue and earnings and highlighted progress on high-profile partnerships, including Sanofi and Pfizer, while also filing an US$82.47 million employee stock offering shelf registration. Now we'll examine how this mix of better-than-expected Q2 resul
Dilution RiskEarningsGuidanceNet IncomePartnershipsShare Price
- Published
- 08 Aug 2026 10:10
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#2828Tone
nasdaq.comDirect company coverage
Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound
Key Points Pfizer's berobenatide appears to be a promising candidate that could challenge Wegovy and Zepbound. There are several other reasons to consider the stock, despite the potential headwinds ahead. 10 stocks we like better than Pfizer › The past few years have been rough on Pfizer(NYSE: PFE). The company has generally posted subpar financial results due to weakness within its coronavirus franchise, which once helped it become the first biopharmaceutical company to achieve $100 billion in annual sales. The drugmaker is looking to turn things around by developing potential blockbuster pro
Clinical TrialsDividendsFinancial ResultsMarketsPharmaceuticalsShare Price
- Published
- 07 Aug 2026 19:48
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#2950Tone
finance.yahoo.comDirect company coverage
NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised
Novavax NVAX incurred a loss of 32 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 36 cents. In the year-ago quarter, the company had recorded earnings per share (EPS) of 62 cents, driven by milestone-related payments. Quarterly revenues totaled $56.7 million, down 76% year over year. Yet, this metric beat the Zacks Consensus Estimate of $50 million. Shares of Novavax have increased 14% so far this year compared with the industry's 4% growth.Zacks Investment Research Image Source: Zacks Investment Research NVAX's Revenue Mix Shifts Toward
Covid 19EarningsEarnings Per ShareMilestonesPharmaceuticalsTotal Revenue
- Published
- 07 Aug 2026 18:18
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.